- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06701903
Studie av ITI-1284 som monoterapibehandling hos pasienter med generalisert angstlidelse
En multisenter, randomisert, dobbeltblind, placebokontrollert studie for å vurdere effektiviteten, sikkerheten og toleransen til ITI-1284 som tilleggsbehandling hos pasienter med generalisert angstlidelse som har en utilstrekkelig respons på behandling med generalisert angstlidelse
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 844-434-4210
- E-post: Participate-In-This-Study1@its.jnj.com
Studiesteder
-
-
-
Blagoevgrad, Bulgaria, 2700
- Rekruttering
- Medical Center Sv Dimitar Blagoevgrad
-
Kardzhali, Bulgaria, 6600
- Rekruttering
- Medical Center Lifemed
-
Pleven, Bulgaria, 5800
- Rekruttering
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgaria, 4004
- Rekruttering
- Medical Center Mentalcare OOD
-
Rousse, Bulgaria, 7003
- Rekruttering
- Mental Health Center - Rousse
-
Sofia, Bulgaria, 1680
- Rekruttering
- Medical Center Intermedica, OOD
-
Sofia, Bulgaria, 1408
- Rekruttering
- DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
-
Sofia, Bulgaria, 1510
- Rekruttering
- Medical Center Hera EOOD
-
Targovishte, Bulgaria, 7700
- Rekruttering
- Medical center - VAS OOD
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- Rekruttering
- University of Alabama at Birmingham
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72211
- Rekruttering
- Woodland International Research Group
-
Rogers, Arkansas, Forente stater, 72758
- Rekruttering
- Woodland Research Northwest
-
-
California
-
Culver City, California, Forente stater, 90230
- Rekruttering
- Proscience Research Group
-
Encino, California, Forente stater, 91316
- Rekruttering
- Wake Research PRI Encino
-
Encino, California, Forente stater, 91316
- Rekruttering
- Leading Edge Research
-
Los Angeles, California, Forente stater, 90025
- Rekruttering
- CalNeuro Research
-
Oceanside, California, Forente stater, 92056
- Rekruttering
- Excell Research Inc
-
Sherman Oaks, California, Forente stater, 91403
- Rekruttering
- California Neuroscience Research
-
Upland, California, Forente stater, 91786
- Fullført
- Pacific Clinical Research Medical Group
-
Walnut Creek, California, Forente stater, 94596
- Rekruttering
- Sunwise Clinical Research
-
-
Connecticut
-
Farmington, Connecticut, Forente stater, 06032
- Rekruttering
- University of Connecticut Health Center
-
-
Florida
-
Gainesville, Florida, Forente stater, 32607
- Fullført
- Sarkis Clinical Trials
-
Miami, Florida, Forente stater, 33176
- Rekruttering
- Miami Dade Medical Research Institute
-
Tampa, Florida, Forente stater, 33613
- Rekruttering
- University of South Florida
-
-
Georgia
-
Decatur, Georgia, Forente stater, 30030
- Rekruttering
- iResearch Atlanta LLC
-
-
Mississippi
-
Flowood, Mississippi, Forente stater, 39232
- Rekruttering
- Precise Clinical Research, Inc.
-
-
New York
-
Brooklyn, New York, Forente stater, 11235
- Rekruttering
- SPRI Clinical Trials, LLC
-
Buffalo, New York, Forente stater, 14215
- Rekruttering
- University of Buffalo
-
Staten Island, New York, Forente stater, 10314
- Rekruttering
- Richmond Behavioral Associates
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University
-
-
Oklahoma
-
Norman, Oklahoma, Forente stater, 73071
- Rekruttering
- Sooner Clinical Research
-
-
Pennsylvania
-
Media, Pennsylvania, Forente stater, 19063
- Rekruttering
- Suburban Research Associates
-
-
Texas
-
Dallas, Texas, Forente stater, 75243
- Rekruttering
- Relaro Medical Trials
-
-
Washington
-
Bellevue, Washington, Forente stater, 98007
- Rekruttering
- Northwest Clinical Research Center
-
-
-
-
-
Bialystok, Polen, 15272
- Rekruttering
- Prywatne Gabinety Lekarskie PROMEDICUS
-
Bydgoszcz, Polen, 85-080
- Rekruttering
- Przychodnia Srodmiescie SP. z o.o.
-
Gdansk, Polen, 80 283
- Rekruttering
- Centrum Zdrowia Alcea
-
Leszno, Polen, 64-100
- Rekruttering
- Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
-
Torun, Polen, 87 100
- Rekruttering
- Agnieszka Nowakowska Rudzka Gabinet Lekarski TCP Neuromed
-
-
-
-
-
Belgrade, Serbia, 11000
- Rekruttering
- University Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- Rekruttering
- Institute of Mental Health Serbia
-
Belgrade, Serbia, 11000
- Rekruttering
- Clinical Center Dr Dragisa Misovic Dedinje
-
Belgrade, Serbia, 11000
- Rekruttering
- University Clinical Center of Serbia 1
-
Kovin, Serbia, 26220
- Rekruttering
- Special Neuropsychiatric Hospital Kovin
-
Kragujevac, Serbia, 34000
- Rekruttering
- University Clinical Center Kragujevac
-
Niš, Serbia, 18000
- Rekruttering
- University Clinical Center NIS
-
Novi Kneževac, Serbia, 23330
- Rekruttering
- Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
-
-
-
-
-
Bratislava, Slovakia, 821 01
- Rekruttering
- Psychiatricka Ambulancia Mentum S.R.O.
-
Rimavská Sobota, Slovakia, 979 01
- Rekruttering
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Svidník, Slovakia, 08901
- Rekruttering
- Centrum Zdravia R.B.K. S.R.O. Poliklinika Medic Sk
-
Vranov nad Topľou, Slovakia, 093 01
- Rekruttering
- Crystal Comfort s.r.o.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Provide written informed consent before the initiation of any study specific procedures;
-
At Screening, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for moderate or severe GAD (current GAD) as confirmed by the Investigator or Sponsor-approved rater using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT), and meets all of the following at Screening and Baseline:
- HAM-A Total score of ≥ 22;
- HAM-A Items 1 (anxious mood) and 2 (tension) scores ≥ 2;
- CGI-S score of ≥ 4;
-
History of inadequate response (< 50% improvement in anxiety symptoms as measured by the modified Antidepressant Treatment Response Questionnaire [ATRQ] for GAD) to at least 2 of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone taken at an adequate dose (that is, at least a minimum total daily dose of paroxetine 20 milligram [mg], venlafaxine XR 75mg, duloxetine 60 mg, escitalopram 10mg, or buspirone 20 mg) and duration (ie, for at least 6 weeks prior to Screening) for the treatment of ongoing GAD symptoms.
Exclusion Criteria:
-
Within the patient's lifetime, has one of the following confirmed DSM-5-TR psychiatric diagnoses:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
MADRS total score > 18 at Screening or Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the C-SSRS within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening;
- At Screening or Baseline MADRS Item 10 score ≥ 5; or
- The patient is considered to be an imminent danger to him/herself or others based on the assessment of the Investigator;
-
Lifetime history of failure to respond to > 3 of the approved treatments for GAD (ie, paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) at an adequate dose (that is, at least a minimum total daily dose of paroxetine 20 mg, venlafaxine XR 75mg, duloxetine 60 mg, escitalopram 10mg, or buspirone 20 mg) and for an adequate duration (ie, at least 6 weeks)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: ITI-1284 10mg
ITI-1284 10 mg tablet, taken once daily, sublingual administration. |
ITI-1284 10 mg tablet, taken once daily, sublingual administration. |
|
Eksperimentell: ITI-1284 20mg
ITI-1284 20 mg tablet, taken once daily, sublingual administration. |
ITI-1284 20 mg tablet, taken once daily, sublingual administration. |
|
Placebo komparator: Placebo
Matching placebo tablet, taken once daily, sublingual administration |
Matching placebo tablet, taken once daily, sublingual administration |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: Week 6
|
The HAM-A Scale is a clinician-rated scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It is comprised of 14 items that are rated on a 5-point scale ranging from 0 = not present to 4 = very severe, disabling symptoms. The HAM-A total score ranges from 0 to 56 with a higher score indicating increased severity of anxiety symptoms. |
Week 6
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Global Impression Scale-Severity (CGI-S)
Tidsramme: Week 6
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients) |
Week 6
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Intra-Cellular Therapies,Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ITI-1284-302
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .